Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.

Baxter, E; Gondara, L; Lohrisch, C; Chia, S; Gelmon, K; Hayes, M; Davidson, A; Tyldesley, S

Baxter, E; Gondara, L; Lohrisch, C; Chia, S; Gelmon, K; Hayes, M; Davidson, A; Tyldesley, S.

Afiliação

Baxter E; Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, BC;
Gondara L; Department of Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver Centre, BC;
Lohrisch C; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC;
Chia S; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC;
Gelmon K; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC;
Hayes M; Department of Pathology, BC Cancer Agency, Vancouver Centre, BC.
Davidson A; Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC;
Tyldesley S; Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, BC;

Curr Oncol ; 22(3): 192-8, 2015 Jun.

Article em En | MEDLINE | ID: mdl-26089718

Palavras-chave

Breast cancer; proliferative markers

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google